DOR BioPharma, Inc. To Host Conference Call On Thursday, January 25 To Discuss Recently Published orBec(R) Phase 3 Clinical Results

DOR BioPharma, Inc. (OTCBB:DORB) (DOR or the Company) announced today that it will host a conference call on Thursday, January 25, 2007 beginning at 11 a.m. Eastern time. Christopher J. Schaber Ph.D., President and Chief Executive Officer and author(s) of the Blood paper will discuss the publication as well as the long-term mortality data. The discussion will include detail on DOR’s 129-patient pivotal Phase 3, randomized, double-blinded, placebo-controlled multi-center clinical trial of orBec® conducted at 16 leading bone marrow/stem cell transplant centers in the U.S. and France; and long-term survival data from its 60-patient Phase 2, randomized, double-blinded, placebo-controlled clinical trial conducted at the Fred Hutchinson Cancer Research Center.